Moderna (MRNA) PT Lowered to $140 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $200.10 -1.25%
Rating Summary:
7 Buy, 20 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
7 Buy, 20 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
JPMorgan analyst Jessica Fye lowered the price target on Moderna (NASDAQ: MRNA) to $140.00 (from $145.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Moderna shares continue to fall after early cancer vaccine data leak
- Tango Therapeutics Inc. (TNGX) PT Raised to $55 at Stifel
- Tango Therapeutics Inc. (TNGX) PT Raised to $45 at Wedbush
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
